Wockhardt’s yet another novel antibiotic MiqnafTM (Nafithromycin) receives favourable recommendation from Subject Expert Committee of Central Drugs Standard Control Organization (CDSCO) for the Treatment for Community – Acquired Bacterial Pneumonia (CABP)
Wockhardt’s another breakthrough antibiotic: once-a – day β – lactam enhancer, WCK 6777 with unique out – patient treatment advantage granted Fast Track designation by US FDA and successfully completes Phase I study conducted by National Institutes of Health, US
Wockhardt’s another breakthrough antibiotic: once – a – day β – lactam enhancer, WCK 6777 with unique out – patient treatment advantage granted Fast Track designation by US FDA and successfully completes Phase I study conducted by National Institutes of Health, US
Dr. Habil Khorakiwala bestowed Lifetime Achievement Award by Integrated Health and Wellbeing Council in Dubai
Dr. Habil Khorakiwala bestowed Lifetime Achievement Award by Integrated Health and Wellbeing Council in Dubai
Wockhardt’s Investigational Drug, Zaynich™ (Zidebactam/Cefepime) cures complex case of meningitis caused by pan – drug resistant super – bug under compassionate use
Wockhardt’s Investigational Drug, Zaynich™ (Zidebactam/Cefepime) cures complex case of meningitis caused by pan – drug resistant super – bug under compassionate use
